Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
8
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
8
×
ipo
8
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
eli lilly
glaxosmithkline
cancer
crispr
medical devices
novartis
scott gottlieb
startups
abbvie
allergan
biogen
What
bio
roundup
8
×
drugs
new
black
cancer
car
crispr
diamond’s
fda
ipo
life
medicine
moves
pharmaceutical
science
therapeutics
week
activity
allogene
appetite
approvals
august
bails
big
biogen
biopharma
biotech
bosley's
bosley’s
brand
bread
bridge
bridgebio
bucks
busy
butter
buyout
capital
cas
Language
unset
Current search:
fda
×
roundup
×
" boston top stories "
×
biotech
×
ipo
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More